Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that leads to dementia and behavioral changes. Extracellular deposition of amyloid plaques (Aβ) and intracellular deposition of neurofibrillary tangles in neurons are the major pathogenicities of AD. However, drugs targeting these therapeutic targets are not effective. Therefore, novel targets for the treatment of AD urgently need to be identified. Expression of the mesoderm-specific transcript (Mest) is regulated by genomic imprinting, where only the paternal allele is active for transcription. We identified hypermethylation on the Mest promoter, which led to a reduction in Mest mRNA levels and activation of Wnt signaling in brain tissues of AD patients. Mest knockout (KO) using the CRIPSR/Cas9 system in mouse embryonic stem cells and P19 embryonic carcinoma cells leads to neuronal differentiation arrest. Depletion of Mest in primary hippocampal neurons via lentivirus expressing shMest or inducible KO system causes neurodegeneration. Notably, depletion of Mest in primary cortical neurons of rats leads to tau phosphorylation at the S199 and T231 sites. Overall, our data suggest that hypermethylation of the Mest promoter may cause or facilitate the progression of AD.

Highlights

  • Misregulation of Wnt/β-catenin signaling is one of the major causes of diseases, due to the role of this pathway in cell proliferation, self-renewal, and cell fate determination during embryonic development and tissue homeostasis in a­ dults[1]

  • Hypermethylation of mesoderm-specific transcript (Mest) promoter and upregulation of Wnt signaling in brain samples of Alzheimer’s disease (AD) patients

  • To check whether sporadic AD patients show any differences in CpG methylation in the Mest promoter regions, we analyzed DNA samples extracted from the temporal cortex of postmortem sporadic AD patients and age-matched controls

Read more

Summary

Introduction

Misregulation of Wnt/β-catenin signaling is one of the major causes of diseases, due to the role of this pathway in cell proliferation, self-renewal, and cell fate determination during embryonic development and tissue homeostasis in a­ dults[1]. We previously showed that Mest acts as a negative regulator of the Wnt/β-catenin pathway by inhibiting the maturation and membrane localization of L­ RP67. Mest is expressed only from the paternal genome, since the maternal gene promoter is methylated. Since aberrant Mest hypermethylation and LOI are often associated with various diseases, it is vital to study the functional role and methylation status of the Mest promoter in AD patients. Epigenome-wide association studies in AD patients suggested that the Mest promoter is potentially hypermethylated in the cortex of AD p­ atients[18]. We investigated the methylation status of the Mest promoter and its effect on Wnt signaling using neurons and brain samples from AD patients. We showed that the Mest promoter was hypermethylated in AD patients and Mest mRNA levels were reduced, while the Wnt target genes were elevated. Mest depletion resulted in the upregulation of Wnt signaling and tau phosphorylation, causing neurodegeneration

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call